Equfina ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
6Parkinson disease2

6. Parkinson disease


Clinical trials : 2,298 Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05225324
(ClinicalTrials.gov)
June 3, 202126/1/2022A Post Marketing Surveillance Study of Equfina Tablet 50 Milligram (mg)Equfina Tablet 50 mg Post Marketing Surveillance ProtocolParkinson Disease;Liver Diseases;Renal InsufficiencyDrug: Equfina 50 mgEisai Korea Inc.NULLRecruiting18 YearsN/AAll600Korea, Republic of
2NCT04724109
(ClinicalTrials.gov)
October 14, 202021/1/2021A Study of Equfina® on the Incidences of Adverse Drug Reactions in Participants With Parkinson's Disease (Including Participants With Hepatic Impairment)Protocol for Study EQF01S: General Drug Use-Results Observational Study of Equfina® TABLETS 50 mg Observational Study on the Incidences of Adverse Drug Reactions in Patients With Parkinson's Disease (Including Patients With Hepatic Impairment)Parkinson DiseaseDrug: EqufinaEisai Co., Ltd.NULLRecruitingN/AN/AAll1000Japan